Kawano Miyuki, Kumagai Keigo, Nishijima Masahiro, Hanada Kentaro
Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
J Biol Chem. 2006 Oct 6;281(40):30279-88. doi: 10.1074/jbc.M605032200. Epub 2006 Aug 8.
Ceramide is synthesized at the endoplasmic reticulum (ER) and transported to the Golgi apparatus by CERT for its conversion to sphingomyelin in mammalian cells. CERT has a pleck-strin homology (PH) domain for Golgi targeting and a START domain catalyzing the intermembrane transfer of ceramide. The region between the two domains contains a short peptide motif designated FFAT, which is supposed to interact with the ER-resident proteins VAP-A and VAP-B. Both VAPs were actually co-immunoprecipitated with CERT, and the CERT/VAP interaction was abolished by mutations in the FFAT motif. These mutations did not affect the Golgi targeting activity of CERT. Whereas mutations of neither the FFAT motif nor the PH domain inhibited the ceramide transfer activity of CERT in a cell-free system, they impaired the ER-to-Golgi transport of ceramide in intact and in semi-intact cells at near endogenous expression levels. By contrast, when overexpressed, both the FFAT motif and the PH domain mutants of CERT substantially supported the transport of ceramide from the ER to the site where sphingomyelin is produced. These results suggest that the Golgi-targeting PH domain and ER-interacting FFAT motif of CERT spatially restrict the random ceramide transfer activity of the START domain in cells.
在哺乳动物细胞中,神经酰胺在内质网(ER)合成,并由CERT转运至高尔基体,以转化为鞘磷脂。CERT具有用于靶向高尔基体的普列克底物蛋白同源(PH)结构域和催化神经酰胺膜间转移的START结构域。这两个结构域之间的区域包含一个名为FFAT的短肽基序,它应该与内质网驻留蛋白VAP - A和VAP - B相互作用。实际上,VAPs都能与CERT进行共免疫沉淀,并且FFAT基序中的突变消除了CERT/VAP相互作用。这些突变不影响CERT的高尔基体靶向活性。在无细胞系统中,FFAT基序和PH结构域的突变均未抑制CERT的神经酰胺转移活性,但在完整细胞和半完整细胞中,在接近内源性表达水平时,它们损害了神经酰胺从内质网到高尔基体的转运。相比之下,当CERT过表达时,其FFAT基序突变体和PH结构域突变体都能显著支持神经酰胺从内质网向鞘磷脂产生部位的转运。这些结果表明,CERT的高尔基体靶向PH结构域和内质网相互作用的FFAT基序在空间上限制了细胞中START结构域随机的神经酰胺转移活性。